SlideShare a Scribd company logo
Documentation In Pharmaceutical
Industry
Name : Gayatri H. Tiwaskar
M.Pharm 1st year (QA)
Guided by : Mrs. Monali N. Dumore
Dadasaheb Balpande College Of Pharmacy ,
Nagpur.
1
Index
Introduction
Specification
Test procedures
Protocols and reports
Distribution records
2
What is Documentation ?
 Document is a written report or record that
provides information
 Documentation is a method of preparing a
written material, which describes the process
in terms of specifications ,instructions etc.
 Document is a piece of written, printed or
electronic matter that provides information or
evidence.
 A Good Documentation is essential part of QA
system .
3
Importance of Documentation
 It provides the working details necessary for
manufacturing, packaging, quality control.
 Reduce the risk of mistakes inherent in verbal
communication.
 They help in decreasing the batch to batch
variation so that quality of product is kept with in
the limit of acceptability.
 Documentation and records are essentials for
obtaining ACCREDIATION ,certification of ISO, and
approval by Federal bodies.
4
Why Documentation?
There is a saying in the pharmaceutical
industry:
'if it hasn't been documented, then it
hasn't happened!'
“YOUR DOCUMENTATION IS AN
ADVERTISEMENT FOR YOUR WORK .
5
Specification
 It is define as a set of parameters expected
to be met by a particular materials, peace of
equipments or any such object.
 Every specification is a company's unique
document and it must have certain common
contents and thereafter each type of
document should have some specific
contents.
6
In case of pharmaceutical products we need
specifications for
 Active and inactive starting materials
 Primary ,printed and other packaging materials
 Intermediate and bulk products
 Finished pharmaceutical products
7
A document specification contains several parts:
 a description of the audience(s) for the
document.
 a detailed outline giving the structure and
contents of the document.
 a work plan showing who is responsible for each
part of the document.
 what the deadlines are for completing each
task.
8
Three purposes for document specifications:
In the workplace, formal document specifications
serve three important functions:
 economy of effort,
 work planning,
 writing organization.
9
Common Contents
1.Name of the company and its address or location.
2.Title of the document viz. “specification”
3.Date of issue and implementation, effective date,
date of preparation, checking and authorisation,
proposed date of review.
4.Names and signature of persons preparing,
checking, and authorising the specification.
5.Unique identification number
6.Pharmacopoieal or other references
7.Circulation list
10
 Specific Contents
1. Specification for active and inactive
starting materials.
2. Specification for packaging materials.
3. Specification for intermediate and bulk
products.
4. Specification for finished products.
11
 Active and inactive starting materials
1.Name of material.
2.Code number references.
3.Pharmacopoial reference to the specific monograph.
4.Qualitative and quantitative requirements,
Physical and chemical characterisation,
microbiological standards and assay etc. Acceptance
limits, covering tests and limits for identity, purity.
5.Name of approved suppliers and original
manufacturer.
12
6.Direction for sampling and testing or reference
to the procedures.
7.Storage conditions and safety precautions.
8.The maximum period of storage before re-
examination.
9.Details of or ref. to test method to be used to
assess compliance with the specification.
13
Packaging material
1.Name of material.
2.Code number reference.
3.Description of nature, dimensions, and materials
of construction of the components with quality
standards, control limits, mould reference,
drawing and details of the test.
4.List of approved supplies/manufacturers.
5.Sampling instructions.
6.storage conditions.
14
7.Frequency of re-examination of stored
components.
8.Details of reference to the test methods to be
used to asses compliance with the specification.
9.A file of reference specimens of current printed
packaging materials should be maintained.
 this should include a colour comparison
standard also.
 each specimens in this must be certified by
the QC personnel.
15
Intermediate and bulk product
The following things should be added to the
common contents.
 It should be available if these are purchased or
dispatched
 or if data obtained from intermediate products
are used in the evaluation of the finished
products.
 These specifications should be similar to starting
material or finished products .
16
Finished Products
1.Name of the product
2.Code number reference
3.Names of the ingredients
4.The formula or reference to the formula
5.A description of dosage forms and package
details.
6.Direction for sampling and testing or reference
to procedures.
17
7.The qualitative and quantitative requirements
with acceptance limits.
8.The storage conditions and precautions, if
applicable.
9.Shelf life.
18
19
20
21
22
Test Procedures
 Universal tests/Criteria
• New drug
substance
1
• New drug
product
2
23
New Drug Substance
The following tests and acceptance criteria are
considered generally applicable to new drug
substances.
 Description : a qualitative statement about
the state (e.g. Solid, liquid) and color of the new
drug substance. If any of these characteristics
change during storage ,this change should be
investigated and appropriate action taken.
24
 Identification : identification testing should
optimally be able to discriminate between
compounds of closely related structure which
are likely to be present.
Identification tests should be specific for the
new drug substance, e.g., infrared
spectroscopy.
25
 Assay : A specific, stability indicating procedure
should be included to determine the content of new
drug substance. In many cases it is possible to
employ the same procedure (e. g., HPLC) for both
assay of the new drug substance and quantitation
of impurities.
26
 Impurities : Organic and inorganic impurities
and residual solvents are included in this category.
(Refer to the ICH Guidelines Impurities in new
drug substances and Residual solvents in
pharmaceuticals for detailed information.)
 as per the ICH guideline Q3 A
27
Classification of impurities
• Organic
• Inorganic
• Residual solvents
28
Organic impurities
This may arise during the manufacturing process
or during the storage, they may be identified or
unidentified and volatile or non-volatile, it
includes,
starting material
by-product
intermediates
degradation product
ligands, catalyst and reagents
29
Inorganic impurities
They may arise in manufacturing process,
they may be known and identified. It
includes,
Reagent, ligands and catalyst
Heavy metals
Inorganic solvents
Other materials ( e.g. charcoal )
30
Residual solvents
This are the organic and inorganic solvents
which is used during the manufacturing, it
may be easily not removed by
manufacturing process.
This are generally of known toxicity.
31
Limits
 Each identified specified impurity.
 Each identified unspecified impurity at
or above 0.1%.
 Any unspecified impurity, with a limit of
not more than 0.1%.
 Total impurities.
32
New Drug Product
 Description : A qualitative description of the
dosage form should be provided ( e.g., size,
shape and color).
 Identification
 Assay
 Impurities
33
 Specific tests/ Criteria
when the tests have an impact on the quality of
drug substance and drug product.
Tests other than this may be needed in
particular situations or as new information
become available.
34
Test
1.
Physicochemic-
al properties
pH of aqueous solution, melting point
and refractive index.
2. Particle size For some new drug substance intended
for use in solid or suspension drug
product, particle size have a significant
effect on dissolution rates,
bioavailability, and/ or stability.
3.Polymeric
form
Some new drug substances exist in
different crystalline form which differ in
their physical properties.
4.Water
content
This test is important in cases where the
new drug substance is known to be
hygroscopic or degraded by moisture
35
Test
5.Inorganic
impurities
Development and based on
knowledge of the manufacturing
process.
6.Microbial
limits
There may be a need to specify the
total count of aerobic
microorganisms.
36
37
Protocol
 Protocols are written records clearly defining the
objectives and methods that will be used for the
validation programs.
 An important part of the protocol is the
description of the testing method including who
will test the system, how they will test it and
what data is to be collected and reported.
38
 Computerized system protocols often include
the three distinct stages as described in PMA
reports:
Installation Qualification (IQ)
Operational Qualification (OQ)
Performance Qualification (PQ).
39
Installation Qualification
40
Operational Qualification
41
Performance Qualification
42
Protocol Changes
Document requirements specifies that who and
how changes can be done to parameters,
thresholds, and acceptance criteria.
It is not impossible to make changes after or
during testing, but these changes must be
properly implemented and approved to be
validated.
43
Protocol for Documentations
1.Serial number of the Batch Manufacturing
Record.
2.Name of the product.
3.Reference to Master Formula Record.
4.Batch/Lot number.
5.Batch/Lot size.
6.Date of commencement of manufacture and
date of completion of manufacture.
44
7.Date of manufacture and assigned date of
expiry.
8.Date of each step in manufacturing.
9.Names of all ingredients with the grade given
by the quality control department.
10.Quality of all ingredients.
11. Control reference numbers for all ingredients.
12. Time and duration of blending, mixing, etc.
whenever applicable.
13. pH of solution whenever applicable.
45
14. Filter integrity testing records.
15. Temperature and humidity records whenever
applicable.
16. Records of plate-counts whenever applicable.
17. Results of pyrogen and/or bacterial endotoxin
& toxicity.
18. Results of weight or volume of drug filled in
containers.
19. Bulk sterility in case of aseptically filled
products.
20. Leak test records.
46
21. Inspection records.
22. Sterilization records including autoclave
leakage test records, load details, date, duration,
temperature, pressure, etc.
23. Container washing records.
24. Total number of containers filled.
25.Total numbers of containers rejected at each
stage.
26. Theoretical yield, permissible yield, actual yield
and variation thereof.
27. Clarification for variation in yield beyond
permissible yield.
47
28. Reference numbers of relevant analytical
reports.
29. Details of reprocessing, if any.
30. Name of all operators carrying out different
activities.
31.Environmental monitoring records.
32. Specimens of printed packaging materials.
33. Records of destruction of rejected containers
printed packaging and testing.
34. Signature of competent technical staff
responsible for manufacture and testing.
48
49
Report
Documentation and records used throughout the
manufacturing process, as well as supporting
processes ( e. g. Quality Control or Quality
Assurance)
It includes,
 Batch Record Forms
 Bill of materials ( BOM)
 Specifications
50
Policies
Protocols
Standard Operation Procedure (SOPs)
Work Instructions (WIs)
Check lists
Forms/ long sheets
Certificates of Analyses or Certificates of
Compliance
Technical transfer reports
Test Methods
Training Assessments
51
Records
Worksheet, notebooks and long books
Manufacturing and packaging instructions
Confidentiality agreements
Change control
Quality system related documents
Quality manual
Validation protocols and reports
Deviation reports
Audit plans
Electronic and hard-copy Quality records
52
Test material related documents including
product specification, test material receipt and
reports.
Personal related documents including training
records.
Facility related documents including floor plans,
environmental specifications.
Deviation forms including unplanned deviations
and system failure investigation.
53
Distribution Records
It contain name and strength of the product and
description of the dosage form, name and address
of the consignee, date quantity shipped, and lot or
control number of the drug product.
Distribution records include a wide range of
documentation such as invoices, bill of lading
customer receipts, and internal warehouse
storage and inventory records.
54
The information required need not be on every
document.
Also customer codes and product codes may be
used as alternates to customers name and
addresses and product names.
Records for distribution shall be maintained in
a manner such that finished batch of a drug can
be traced to the retain level to facilitate prompt
and complete recall of the batch, if and when
necessary.
55
Document Required
 SOP on distribution of finished
products for sale or sample.
 Records of distribution.
56
57
58
Thank You !
59

More Related Content

What's hot

Issue facing modern drug packaging, selection & evaluation of pharmaceuti...
Issue facing modern drug packaging, selection & evaluation of pharmaceuti...Issue facing modern drug packaging, selection & evaluation of pharmaceuti...
Issue facing modern drug packaging, selection & evaluation of pharmaceuti...
HEALY LAD
 
cGMP Guidelines According to Schedule M
cGMP Guidelines According to Schedule McGMP Guidelines According to Schedule M
cGMP Guidelines According to Schedule M
ANKUSH JADHAV
 
Process validation and its types
Process validation and its typesProcess validation and its types
Process validation and its types
Anjali9410
 
Pharmaceutical Industry Development
Pharmaceutical Industry DevelopmentPharmaceutical Industry Development
Pharmaceutical Industry Development
RohitKoli27
 
Out of specification (oos)1
Out of specification (oos)1Out of specification (oos)1
Out of specification (oos)1
Dr. Ravi Kinhikar
 
USFDA guidelines of glp for non clinical testing laboratories
USFDA guidelines of glp for non clinical testing laboratoriesUSFDA guidelines of glp for non clinical testing laboratories
USFDA guidelines of glp for non clinical testing laboratories
swrk
 
Validation master plan
Validation master planValidation master plan
Pre formulation protocol
Pre formulation protocolPre formulation protocol
Pre formulation protocol
Amruta Balekundri
 
Pharmaceutical inspection convention M. Pharmacy
Pharmaceutical inspection convention M. PharmacyPharmaceutical inspection convention M. Pharmacy
Pharmaceutical inspection convention M. Pharmacy
priyankapatil7896
 
Process validation of tablets
Process validation of tabletsProcess validation of tablets
Process validation of tablets
Dinesh Kumar M Prajapati
 
cGMP regulations & QA function.pptx
cGMP regulations &  QA function.pptxcGMP regulations &  QA function.pptx
cGMP regulations & QA function.pptx
Dhruvi50
 
Documentation in Pharmaceutical Industry
Documentation in Pharmaceutical IndustryDocumentation in Pharmaceutical Industry
Documentation in Pharmaceutical Industry
Navaneethakrishnan Palaniappan
 
Pharmaceutical Packaging
Pharmaceutical PackagingPharmaceutical Packaging
Pharmaceutical Packaging
rishitiwari42
 
BACPAC
BACPACBACPAC
BACPAC
Dhruvi50
 
Pharmaceutical Qualification & Validation
Pharmaceutical Qualification & ValidationPharmaceutical Qualification & Validation
Pharmaceutical Qualification & Validation
Pharmaceutical
 
Ich guideline for stability testing
Ich guideline for stability testingIch guideline for stability testing
Ich guideline for stability testing
Shubham Gore
 
Pharmaceutical documentation
Pharmaceutical documentationPharmaceutical documentation
Pharmaceutical documentation
K V NANDA KUMAR
 
Various techniques for study of Crystal Properties
Various techniques for study of Crystal PropertiesVarious techniques for study of Crystal Properties
Various techniques for study of Crystal Properties
Cooling Crystal
 
cGMP Guidelines according to USFDA
cGMP Guidelines according to USFDAcGMP Guidelines according to USFDA
cGMP Guidelines according to USFDA
MANIKANDAN V
 
current good manufacturing practices as per who
current good manufacturing practices as per whocurrent good manufacturing practices as per who
current good manufacturing practices as per who
Dilipkumar Velde
 

What's hot (20)

Issue facing modern drug packaging, selection & evaluation of pharmaceuti...
Issue facing modern drug packaging, selection & evaluation of pharmaceuti...Issue facing modern drug packaging, selection & evaluation of pharmaceuti...
Issue facing modern drug packaging, selection & evaluation of pharmaceuti...
 
cGMP Guidelines According to Schedule M
cGMP Guidelines According to Schedule McGMP Guidelines According to Schedule M
cGMP Guidelines According to Schedule M
 
Process validation and its types
Process validation and its typesProcess validation and its types
Process validation and its types
 
Pharmaceutical Industry Development
Pharmaceutical Industry DevelopmentPharmaceutical Industry Development
Pharmaceutical Industry Development
 
Out of specification (oos)1
Out of specification (oos)1Out of specification (oos)1
Out of specification (oos)1
 
USFDA guidelines of glp for non clinical testing laboratories
USFDA guidelines of glp for non clinical testing laboratoriesUSFDA guidelines of glp for non clinical testing laboratories
USFDA guidelines of glp for non clinical testing laboratories
 
Validation master plan
Validation master planValidation master plan
Validation master plan
 
Pre formulation protocol
Pre formulation protocolPre formulation protocol
Pre formulation protocol
 
Pharmaceutical inspection convention M. Pharmacy
Pharmaceutical inspection convention M. PharmacyPharmaceutical inspection convention M. Pharmacy
Pharmaceutical inspection convention M. Pharmacy
 
Process validation of tablets
Process validation of tabletsProcess validation of tablets
Process validation of tablets
 
cGMP regulations & QA function.pptx
cGMP regulations &  QA function.pptxcGMP regulations &  QA function.pptx
cGMP regulations & QA function.pptx
 
Documentation in Pharmaceutical Industry
Documentation in Pharmaceutical IndustryDocumentation in Pharmaceutical Industry
Documentation in Pharmaceutical Industry
 
Pharmaceutical Packaging
Pharmaceutical PackagingPharmaceutical Packaging
Pharmaceutical Packaging
 
BACPAC
BACPACBACPAC
BACPAC
 
Pharmaceutical Qualification & Validation
Pharmaceutical Qualification & ValidationPharmaceutical Qualification & Validation
Pharmaceutical Qualification & Validation
 
Ich guideline for stability testing
Ich guideline for stability testingIch guideline for stability testing
Ich guideline for stability testing
 
Pharmaceutical documentation
Pharmaceutical documentationPharmaceutical documentation
Pharmaceutical documentation
 
Various techniques for study of Crystal Properties
Various techniques for study of Crystal PropertiesVarious techniques for study of Crystal Properties
Various techniques for study of Crystal Properties
 
cGMP Guidelines according to USFDA
cGMP Guidelines according to USFDAcGMP Guidelines according to USFDA
cGMP Guidelines according to USFDA
 
current good manufacturing practices as per who
current good manufacturing practices as per whocurrent good manufacturing practices as per who
current good manufacturing practices as per who
 

Similar to Documentation in pharmaceutical industry

Quality control and quality assurance.pptx
Quality control and quality assurance.pptxQuality control and quality assurance.pptx
Quality control and quality assurance.pptx
manoharkasde123
 
Docmentation complete
Docmentation completeDocmentation complete
Docmentation complete
Malla Reddy College of Pharmacy
 
Presentation1.pptx final
Presentation1.pptx finalPresentation1.pptx final
Presentation1.pptx final
shivani gupta
 
Documentation with respect to release of finished pharmaceutical product
Documentation with respect to release of finished pharmaceutical productDocumentation with respect to release of finished pharmaceutical product
Documentation with respect to release of finished pharmaceutical product
MadhuraNewrekar
 
Raw Material Validation
Raw Material ValidationRaw Material Validation
Raw Material Validation
Hiron Devnath
 
Quality Management system, QC vs QA, Pharmacopoeia.pdf
Quality Management system, QC vs QA, Pharmacopoeia.pdfQuality Management system, QC vs QA, Pharmacopoeia.pdf
Quality Management system, QC vs QA, Pharmacopoeia.pdf
Md Mohebullah Sarker Maruf
 
documentation in pharmaceutical industry.pdf
documentation in pharmaceutical industry.pdfdocumentation in pharmaceutical industry.pdf
documentation in pharmaceutical industry.pdf
SoumiliPaul1
 
analsis1.pptx
analsis1.pptxanalsis1.pptx
analsis1.pptx
MekuanentTerefe1
 
Q6 guidelines
Q6 guidelinesQ6 guidelines
Q6 guidelines
Anjali Aji
 
special emphasis on Q series guidelines
special emphasis on Q series guidelines special emphasis on Q series guidelines
special emphasis on Q series guidelines
srikrupa institute of pharmaceutical analysis
 
C gmp0
C gmp0C gmp0
C gmp0
rahul seth
 
1.3 ICH .pdf
1.3 ICH .pdf1.3 ICH .pdf
1.3 ICH .pdf
KoriyaKrupali1
 
product formulation and development
product formulation and developmentproduct formulation and development
product formulation and development
kalyaniArisettti
 
EU(European Union) and ICH Guidelines
EU(European Union) and ICH GuidelinesEU(European Union) and ICH Guidelines
EU(European Union) and ICH Guidelines
D.R. Chandravanshi
 
02Good Laboratory Practice (GLP)(1).pptx
02Good Laboratory Practice (GLP)(1).pptx02Good Laboratory Practice (GLP)(1).pptx
02Good Laboratory Practice (GLP)(1).pptx
hailemeskelteshome
 
ICH Guideline Q8 Pharmaceutical Development
ICH Guideline Q8  Pharmaceutical DevelopmentICH Guideline Q8  Pharmaceutical Development
ICH Guideline Q8 Pharmaceutical Development
BINDIYA PATEL
 
Q3 B R2 ICH Guideline
Q3 B R2 ICH GuidelineQ3 B R2 ICH Guideline
Q3 B R2 ICH Guideline
Mahesh Chokshi
 
Documentation
DocumentationDocumentation
Documentation
Dr Gajanan Sanap
 
GMP and Quality assurance PDF.pdf
GMP and Quality assurance PDF.pdfGMP and Quality assurance PDF.pdf
GMP and Quality assurance PDF.pdf
ravikumarbme
 
ICH GUIDELINE Q 23024671010_RA.pptx
ICH GUIDELINE Q      23024671010_RA.pptxICH GUIDELINE Q      23024671010_RA.pptx
ICH GUIDELINE Q 23024671010_RA.pptx
70KRISHPATEL
 

Similar to Documentation in pharmaceutical industry (20)

Quality control and quality assurance.pptx
Quality control and quality assurance.pptxQuality control and quality assurance.pptx
Quality control and quality assurance.pptx
 
Docmentation complete
Docmentation completeDocmentation complete
Docmentation complete
 
Presentation1.pptx final
Presentation1.pptx finalPresentation1.pptx final
Presentation1.pptx final
 
Documentation with respect to release of finished pharmaceutical product
Documentation with respect to release of finished pharmaceutical productDocumentation with respect to release of finished pharmaceutical product
Documentation with respect to release of finished pharmaceutical product
 
Raw Material Validation
Raw Material ValidationRaw Material Validation
Raw Material Validation
 
Quality Management system, QC vs QA, Pharmacopoeia.pdf
Quality Management system, QC vs QA, Pharmacopoeia.pdfQuality Management system, QC vs QA, Pharmacopoeia.pdf
Quality Management system, QC vs QA, Pharmacopoeia.pdf
 
documentation in pharmaceutical industry.pdf
documentation in pharmaceutical industry.pdfdocumentation in pharmaceutical industry.pdf
documentation in pharmaceutical industry.pdf
 
analsis1.pptx
analsis1.pptxanalsis1.pptx
analsis1.pptx
 
Q6 guidelines
Q6 guidelinesQ6 guidelines
Q6 guidelines
 
special emphasis on Q series guidelines
special emphasis on Q series guidelines special emphasis on Q series guidelines
special emphasis on Q series guidelines
 
C gmp0
C gmp0C gmp0
C gmp0
 
1.3 ICH .pdf
1.3 ICH .pdf1.3 ICH .pdf
1.3 ICH .pdf
 
product formulation and development
product formulation and developmentproduct formulation and development
product formulation and development
 
EU(European Union) and ICH Guidelines
EU(European Union) and ICH GuidelinesEU(European Union) and ICH Guidelines
EU(European Union) and ICH Guidelines
 
02Good Laboratory Practice (GLP)(1).pptx
02Good Laboratory Practice (GLP)(1).pptx02Good Laboratory Practice (GLP)(1).pptx
02Good Laboratory Practice (GLP)(1).pptx
 
ICH Guideline Q8 Pharmaceutical Development
ICH Guideline Q8  Pharmaceutical DevelopmentICH Guideline Q8  Pharmaceutical Development
ICH Guideline Q8 Pharmaceutical Development
 
Q3 B R2 ICH Guideline
Q3 B R2 ICH GuidelineQ3 B R2 ICH Guideline
Q3 B R2 ICH Guideline
 
Documentation
DocumentationDocumentation
Documentation
 
GMP and Quality assurance PDF.pdf
GMP and Quality assurance PDF.pdfGMP and Quality assurance PDF.pdf
GMP and Quality assurance PDF.pdf
 
ICH GUIDELINE Q 23024671010_RA.pptx
ICH GUIDELINE Q      23024671010_RA.pptxICH GUIDELINE Q      23024671010_RA.pptx
ICH GUIDELINE Q 23024671010_RA.pptx
 

Recently uploaded

Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School DistrictPride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
David Douglas School District
 
The History of Stoke Newington Street Names
The History of Stoke Newington Street NamesThe History of Stoke Newington Street Names
The History of Stoke Newington Street Names
History of Stoke Newington
 
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective UpskillingYour Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Excellence Foundation for South Sudan
 
writing about opinions about Australia the movie
writing about opinions about Australia the moviewriting about opinions about Australia the movie
writing about opinions about Australia the movie
Nicholas Montgomery
 
Main Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docxMain Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docx
adhitya5119
 
PCOS corelations and management through Ayurveda.
PCOS corelations and management through Ayurveda.PCOS corelations and management through Ayurveda.
PCOS corelations and management through Ayurveda.
Dr. Shivangi Singh Parihar
 
Liberal Approach to the Study of Indian Politics.pdf
Liberal Approach to the Study of Indian Politics.pdfLiberal Approach to the Study of Indian Politics.pdf
Liberal Approach to the Study of Indian Politics.pdf
WaniBasim
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
amberjdewit93
 
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
IreneSebastianRueco1
 
Smart-Money for SMC traders good time and ICT
Smart-Money for SMC traders good time and ICTSmart-Money for SMC traders good time and ICT
Smart-Money for SMC traders good time and ICT
simonomuemu
 
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdfANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
Priyankaranawat4
 
Hindi varnamala | hindi alphabet PPT.pdf
Hindi varnamala | hindi alphabet PPT.pdfHindi varnamala | hindi alphabet PPT.pdf
Hindi varnamala | hindi alphabet PPT.pdf
Dr. Mulla Adam Ali
 
The Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collectionThe Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collection
Israel Genealogy Research Association
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
Assessment and Planning in Educational technology.pptx
Assessment and Planning in Educational technology.pptxAssessment and Planning in Educational technology.pptx
Assessment and Planning in Educational technology.pptx
Kavitha Krishnan
 
A Independência da América Espanhola LAPBOOK.pdf
A Independência da América Espanhola LAPBOOK.pdfA Independência da América Espanhola LAPBOOK.pdf
A Independência da América Espanhola LAPBOOK.pdf
Jean Carlos Nunes Paixão
 
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdfবাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
eBook.com.bd (প্রয়োজনীয় বাংলা বই)
 
Advanced Java[Extra Concepts, Not Difficult].docx
Advanced Java[Extra Concepts, Not Difficult].docxAdvanced Java[Extra Concepts, Not Difficult].docx
Advanced Java[Extra Concepts, Not Difficult].docx
adhitya5119
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 

Recently uploaded (20)

Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School DistrictPride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
 
The History of Stoke Newington Street Names
The History of Stoke Newington Street NamesThe History of Stoke Newington Street Names
The History of Stoke Newington Street Names
 
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective UpskillingYour Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective Upskilling
 
writing about opinions about Australia the movie
writing about opinions about Australia the moviewriting about opinions about Australia the movie
writing about opinions about Australia the movie
 
Main Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docxMain Java[All of the Base Concepts}.docx
Main Java[All of the Base Concepts}.docx
 
PCOS corelations and management through Ayurveda.
PCOS corelations and management through Ayurveda.PCOS corelations and management through Ayurveda.
PCOS corelations and management through Ayurveda.
 
Liberal Approach to the Study of Indian Politics.pdf
Liberal Approach to the Study of Indian Politics.pdfLiberal Approach to the Study of Indian Politics.pdf
Liberal Approach to the Study of Indian Politics.pdf
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
Digital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental DesignDigital Artefact 1 - Tiny Home Environmental Design
Digital Artefact 1 - Tiny Home Environmental Design
 
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
RPMS TEMPLATE FOR SCHOOL YEAR 2023-2024 FOR TEACHER 1 TO TEACHER 3
 
Smart-Money for SMC traders good time and ICT
Smart-Money for SMC traders good time and ICTSmart-Money for SMC traders good time and ICT
Smart-Money for SMC traders good time and ICT
 
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdfANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
ANATOMY AND BIOMECHANICS OF HIP JOINT.pdf
 
Hindi varnamala | hindi alphabet PPT.pdf
Hindi varnamala | hindi alphabet PPT.pdfHindi varnamala | hindi alphabet PPT.pdf
Hindi varnamala | hindi alphabet PPT.pdf
 
The Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collectionThe Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collection
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
Assessment and Planning in Educational technology.pptx
Assessment and Planning in Educational technology.pptxAssessment and Planning in Educational technology.pptx
Assessment and Planning in Educational technology.pptx
 
A Independência da América Espanhola LAPBOOK.pdf
A Independência da América Espanhola LAPBOOK.pdfA Independência da América Espanhola LAPBOOK.pdf
A Independência da América Espanhola LAPBOOK.pdf
 
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdfবাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
বাংলাদেশ অর্থনৈতিক সমীক্ষা (Economic Review) ২০২৪ UJS App.pdf
 
Advanced Java[Extra Concepts, Not Difficult].docx
Advanced Java[Extra Concepts, Not Difficult].docxAdvanced Java[Extra Concepts, Not Difficult].docx
Advanced Java[Extra Concepts, Not Difficult].docx
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 

Documentation in pharmaceutical industry

  • 1. Documentation In Pharmaceutical Industry Name : Gayatri H. Tiwaskar M.Pharm 1st year (QA) Guided by : Mrs. Monali N. Dumore Dadasaheb Balpande College Of Pharmacy , Nagpur. 1
  • 3. What is Documentation ?  Document is a written report or record that provides information  Documentation is a method of preparing a written material, which describes the process in terms of specifications ,instructions etc.  Document is a piece of written, printed or electronic matter that provides information or evidence.  A Good Documentation is essential part of QA system . 3
  • 4. Importance of Documentation  It provides the working details necessary for manufacturing, packaging, quality control.  Reduce the risk of mistakes inherent in verbal communication.  They help in decreasing the batch to batch variation so that quality of product is kept with in the limit of acceptability.  Documentation and records are essentials for obtaining ACCREDIATION ,certification of ISO, and approval by Federal bodies. 4
  • 5. Why Documentation? There is a saying in the pharmaceutical industry: 'if it hasn't been documented, then it hasn't happened!' “YOUR DOCUMENTATION IS AN ADVERTISEMENT FOR YOUR WORK . 5
  • 6. Specification  It is define as a set of parameters expected to be met by a particular materials, peace of equipments or any such object.  Every specification is a company's unique document and it must have certain common contents and thereafter each type of document should have some specific contents. 6
  • 7. In case of pharmaceutical products we need specifications for  Active and inactive starting materials  Primary ,printed and other packaging materials  Intermediate and bulk products  Finished pharmaceutical products 7
  • 8. A document specification contains several parts:  a description of the audience(s) for the document.  a detailed outline giving the structure and contents of the document.  a work plan showing who is responsible for each part of the document.  what the deadlines are for completing each task. 8
  • 9. Three purposes for document specifications: In the workplace, formal document specifications serve three important functions:  economy of effort,  work planning,  writing organization. 9
  • 10. Common Contents 1.Name of the company and its address or location. 2.Title of the document viz. “specification” 3.Date of issue and implementation, effective date, date of preparation, checking and authorisation, proposed date of review. 4.Names and signature of persons preparing, checking, and authorising the specification. 5.Unique identification number 6.Pharmacopoieal or other references 7.Circulation list 10
  • 11.  Specific Contents 1. Specification for active and inactive starting materials. 2. Specification for packaging materials. 3. Specification for intermediate and bulk products. 4. Specification for finished products. 11
  • 12.  Active and inactive starting materials 1.Name of material. 2.Code number references. 3.Pharmacopoial reference to the specific monograph. 4.Qualitative and quantitative requirements, Physical and chemical characterisation, microbiological standards and assay etc. Acceptance limits, covering tests and limits for identity, purity. 5.Name of approved suppliers and original manufacturer. 12
  • 13. 6.Direction for sampling and testing or reference to the procedures. 7.Storage conditions and safety precautions. 8.The maximum period of storage before re- examination. 9.Details of or ref. to test method to be used to assess compliance with the specification. 13
  • 14. Packaging material 1.Name of material. 2.Code number reference. 3.Description of nature, dimensions, and materials of construction of the components with quality standards, control limits, mould reference, drawing and details of the test. 4.List of approved supplies/manufacturers. 5.Sampling instructions. 6.storage conditions. 14
  • 15. 7.Frequency of re-examination of stored components. 8.Details of reference to the test methods to be used to asses compliance with the specification. 9.A file of reference specimens of current printed packaging materials should be maintained.  this should include a colour comparison standard also.  each specimens in this must be certified by the QC personnel. 15
  • 16. Intermediate and bulk product The following things should be added to the common contents.  It should be available if these are purchased or dispatched  or if data obtained from intermediate products are used in the evaluation of the finished products.  These specifications should be similar to starting material or finished products . 16
  • 17. Finished Products 1.Name of the product 2.Code number reference 3.Names of the ingredients 4.The formula or reference to the formula 5.A description of dosage forms and package details. 6.Direction for sampling and testing or reference to procedures. 17
  • 18. 7.The qualitative and quantitative requirements with acceptance limits. 8.The storage conditions and precautions, if applicable. 9.Shelf life. 18
  • 19. 19
  • 20. 20
  • 21. 21
  • 22. 22
  • 23. Test Procedures  Universal tests/Criteria • New drug substance 1 • New drug product 2 23
  • 24. New Drug Substance The following tests and acceptance criteria are considered generally applicable to new drug substances.  Description : a qualitative statement about the state (e.g. Solid, liquid) and color of the new drug substance. If any of these characteristics change during storage ,this change should be investigated and appropriate action taken. 24
  • 25.  Identification : identification testing should optimally be able to discriminate between compounds of closely related structure which are likely to be present. Identification tests should be specific for the new drug substance, e.g., infrared spectroscopy. 25
  • 26.  Assay : A specific, stability indicating procedure should be included to determine the content of new drug substance. In many cases it is possible to employ the same procedure (e. g., HPLC) for both assay of the new drug substance and quantitation of impurities. 26
  • 27.  Impurities : Organic and inorganic impurities and residual solvents are included in this category. (Refer to the ICH Guidelines Impurities in new drug substances and Residual solvents in pharmaceuticals for detailed information.)  as per the ICH guideline Q3 A 27
  • 28. Classification of impurities • Organic • Inorganic • Residual solvents 28
  • 29. Organic impurities This may arise during the manufacturing process or during the storage, they may be identified or unidentified and volatile or non-volatile, it includes, starting material by-product intermediates degradation product ligands, catalyst and reagents 29
  • 30. Inorganic impurities They may arise in manufacturing process, they may be known and identified. It includes, Reagent, ligands and catalyst Heavy metals Inorganic solvents Other materials ( e.g. charcoal ) 30
  • 31. Residual solvents This are the organic and inorganic solvents which is used during the manufacturing, it may be easily not removed by manufacturing process. This are generally of known toxicity. 31
  • 32. Limits  Each identified specified impurity.  Each identified unspecified impurity at or above 0.1%.  Any unspecified impurity, with a limit of not more than 0.1%.  Total impurities. 32
  • 33. New Drug Product  Description : A qualitative description of the dosage form should be provided ( e.g., size, shape and color).  Identification  Assay  Impurities 33
  • 34.  Specific tests/ Criteria when the tests have an impact on the quality of drug substance and drug product. Tests other than this may be needed in particular situations or as new information become available. 34
  • 35. Test 1. Physicochemic- al properties pH of aqueous solution, melting point and refractive index. 2. Particle size For some new drug substance intended for use in solid or suspension drug product, particle size have a significant effect on dissolution rates, bioavailability, and/ or stability. 3.Polymeric form Some new drug substances exist in different crystalline form which differ in their physical properties. 4.Water content This test is important in cases where the new drug substance is known to be hygroscopic or degraded by moisture 35
  • 36. Test 5.Inorganic impurities Development and based on knowledge of the manufacturing process. 6.Microbial limits There may be a need to specify the total count of aerobic microorganisms. 36
  • 37. 37
  • 38. Protocol  Protocols are written records clearly defining the objectives and methods that will be used for the validation programs.  An important part of the protocol is the description of the testing method including who will test the system, how they will test it and what data is to be collected and reported. 38
  • 39.  Computerized system protocols often include the three distinct stages as described in PMA reports: Installation Qualification (IQ) Operational Qualification (OQ) Performance Qualification (PQ). 39
  • 43. Protocol Changes Document requirements specifies that who and how changes can be done to parameters, thresholds, and acceptance criteria. It is not impossible to make changes after or during testing, but these changes must be properly implemented and approved to be validated. 43
  • 44. Protocol for Documentations 1.Serial number of the Batch Manufacturing Record. 2.Name of the product. 3.Reference to Master Formula Record. 4.Batch/Lot number. 5.Batch/Lot size. 6.Date of commencement of manufacture and date of completion of manufacture. 44
  • 45. 7.Date of manufacture and assigned date of expiry. 8.Date of each step in manufacturing. 9.Names of all ingredients with the grade given by the quality control department. 10.Quality of all ingredients. 11. Control reference numbers for all ingredients. 12. Time and duration of blending, mixing, etc. whenever applicable. 13. pH of solution whenever applicable. 45
  • 46. 14. Filter integrity testing records. 15. Temperature and humidity records whenever applicable. 16. Records of plate-counts whenever applicable. 17. Results of pyrogen and/or bacterial endotoxin & toxicity. 18. Results of weight or volume of drug filled in containers. 19. Bulk sterility in case of aseptically filled products. 20. Leak test records. 46
  • 47. 21. Inspection records. 22. Sterilization records including autoclave leakage test records, load details, date, duration, temperature, pressure, etc. 23. Container washing records. 24. Total number of containers filled. 25.Total numbers of containers rejected at each stage. 26. Theoretical yield, permissible yield, actual yield and variation thereof. 27. Clarification for variation in yield beyond permissible yield. 47
  • 48. 28. Reference numbers of relevant analytical reports. 29. Details of reprocessing, if any. 30. Name of all operators carrying out different activities. 31.Environmental monitoring records. 32. Specimens of printed packaging materials. 33. Records of destruction of rejected containers printed packaging and testing. 34. Signature of competent technical staff responsible for manufacture and testing. 48
  • 49. 49
  • 50. Report Documentation and records used throughout the manufacturing process, as well as supporting processes ( e. g. Quality Control or Quality Assurance) It includes,  Batch Record Forms  Bill of materials ( BOM)  Specifications 50
  • 51. Policies Protocols Standard Operation Procedure (SOPs) Work Instructions (WIs) Check lists Forms/ long sheets Certificates of Analyses or Certificates of Compliance Technical transfer reports Test Methods Training Assessments 51
  • 52. Records Worksheet, notebooks and long books Manufacturing and packaging instructions Confidentiality agreements Change control Quality system related documents Quality manual Validation protocols and reports Deviation reports Audit plans Electronic and hard-copy Quality records 52
  • 53. Test material related documents including product specification, test material receipt and reports. Personal related documents including training records. Facility related documents including floor plans, environmental specifications. Deviation forms including unplanned deviations and system failure investigation. 53
  • 54. Distribution Records It contain name and strength of the product and description of the dosage form, name and address of the consignee, date quantity shipped, and lot or control number of the drug product. Distribution records include a wide range of documentation such as invoices, bill of lading customer receipts, and internal warehouse storage and inventory records. 54
  • 55. The information required need not be on every document. Also customer codes and product codes may be used as alternates to customers name and addresses and product names. Records for distribution shall be maintained in a manner such that finished batch of a drug can be traced to the retain level to facilitate prompt and complete recall of the batch, if and when necessary. 55
  • 56. Document Required  SOP on distribution of finished products for sale or sample.  Records of distribution. 56
  • 57. 57
  • 58. 58